Yescarta / FKC876 Approved in China for Adult Patients With ≥3L R/R DLBCL
On Wednesday, June 23, Gilead announced (press release) that Yescarta (FKC876 / Yikeilen) has been approved by the Chinese NMPA for adult patients in ≥3L r/r DLBCL. Of note, Yescarta has become the first approved CAR-T in China. Below, Celltelligence provides insights on Yescarta’s Chinese regulatory history including which CAR-T could be approved next, while discussing the potential hurdles facing CAR-T reimbursement in China.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.